Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID‐19 pandemic and allergen immunotherapy—an EAACI survey
Oliver Pfaar, Ioana Agache, Matteo Bonini, et al.
Allergy (2021) Vol. 76, Iss. 11, pp. 3504-3516
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Sarah K. Wise, Cecelia Damask, Lauren T. Roland, et al.
International Forum of Allergy & Rhinology (2023) Vol. 13, Iss. 4, pp. 293-859
Open Access | Times Cited: 225
One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence
Oliver Pfaar, Jean Bousquet, Stephen R. Durham, et al.
Allergy (2021) Vol. 77, Iss. 2, pp. 454-468
Open Access | Times Cited: 64
A bird's eye view on the role of dendritic cells in SARS‐CoV‐2 infection: Perspectives for immune‐based vaccines
Domenico Galati, Serena Zanotta, Ludovica Capitelli, et al.
Allergy (2021) Vol. 77, Iss. 1, pp. 100-110
Open Access | Times Cited: 35
A retrospective study regarding the influence of COVID-19 disease on asthma
Ioana Adriana Muntean, Polliana Mihaela Leru, Irena Pintea, et al.
BMC Pulmonary Medicine (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 11
Real‐World Impact of COVID‐19 on Subcutaneous Immunotherapy Persistence and Efficacy in Allergic Rhinitis
Xuan Yuan, Liyuan Liu, Benjian Zhang, et al.
Allergy (2025)
Closed Access
Allergic patients during the COVID‐19 pandemic—Clinical practical considerations: An European Academy of Allergy and Clinical Immunology survey
Montserrat Álvaro‐Lozano, Mónica Sandoval, Mattia Giovannini, et al.
Clinical and Translational Allergy (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 18
Allergic diseases and immunodeficiencies in children, lessons learnt from COVID‐19 pandemic by 2022: A statement from the EAACI‐section on pediatrics
Daniel Munblit, Matthew Greenhawt, Helen A. Brough, et al.
Pediatric Allergy and Immunology (2022) Vol. 33, Iss. 10
Open Access | Times Cited: 16
Telemedicine with special focus on allergic diseases and asthma—Status 2022: An EAACI position paper
Sylwia Smolińska, Florin‐Dan Popescu, Elena Izquierdo, et al.
Allergy (2023) Vol. 79, Iss. 4, pp. 777-792
Open Access | Times Cited: 10
Real‐life impact of COVID‐19 pandemic lockdown on the management of pediatric and adult asthma: A survey by the EAACI Asthma Section
Ibón Eguíluz-Gracia, Maarten van den Berge, Cristina Boccabella, et al.
Allergy (2021) Vol. 76, Iss. 9, pp. 2776-2784
Open Access | Times Cited: 23
Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies—Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology taskforce
Julijana Asllani, Dimitrios Mitsias, George Ν. Konstantinou, et al.
Clinical and Translational Allergy (2023) Vol. 13, Iss. 6
Open Access | Times Cited: 8
Adherence to subcutaneous immunotherapy with aeroallergens in real‐life practice during the COVID‐19 pandemic
Osman Ozan Yeğit, Semra Demir, Derya Ünal, et al.
Allergy (2021) Vol. 77, Iss. 1, pp. 197-206
Open Access | Times Cited: 16
111 years of allergen-immunotherapy: A long and successful history of the only available disease-modifier in allergic diseases
Jan Gutermuth, Martine Grosber, Oliver Pfaar, et al.
Allergologie select (2022) Vol. 6, Iss. 01, pp. 248-258
Open Access | Times Cited: 11
Allergen immunotherapy during the COVID‐19 pandemic—A survey of the German Society for Allergy and Clinical Immunology
Oliver Pfaar, Eckard Hamelmann, Ludger Klimek, et al.
Clinical and Translational Allergy (2022) Vol. 12, Iss. 3
Open Access | Times Cited: 10
Clinical endpoints in allergen immunotherapy: State of the art 2022
Roy Gerth van Wijk, Ludger Klimek, Oliver Pfaar
Allergologie select (2023) Vol. 7, Iss. 1, pp. 39-46
Open Access | Times Cited: 4
Four years into the COVID‐19 pandemic: Timely published articles for patient care and EAACI's leadership role
Marı́a José Torres, Ludger Klimek, Ioana Agache, et al.
Allergy (2024) Vol. 79, Iss. 8, pp. 2031-2033
Open Access | Times Cited: 1
Vaccine development strategies and impact
Arijit Nandi, Yadu Nandan Dey, Debalina Maity, et al.
Elsevier eBooks (2024), pp. 149-180
Closed Access | Times Cited: 1
RIAIT (Italian Registry of Allergen Immunotherapy): Protocol for a New Tool in a New Vision of Disease-Modifying Therapy for Allergists
Giovanni Costanzo, Cristiano Caruso, Giovanni Paoletti, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 8, pp. 854-854
Open Access | Times Cited: 1
COVID-19 vaccination and allergen immunotherapy (AIT) - A position paper of the German Society for Applied Allergology (AeDA) and the German Society for Allergology and Clinical Immunology (DGAKI)
Ludger Klimek, Oliver Pfaar, Eckard Hamelmann, et al.
Allergologie select (2021) Vol. 5, Iss. 01, pp. 251-259
Open Access | Times Cited: 10
Recent advances and developments in COVID‐19 in the context of allergic diseases
Mei Ding, Xiang Dong, Yuanli Sun, et al.
Clinical and Translational Allergy (2021) Vol. 11, Iss. 7
Open Access | Times Cited: 7
Real‐life report of allergen immunotherapy management during the COVID‐19 outbreak in France and Spain
Pablo Rodríguez del Río, Davide Caimmi, P Rico, et al.
Clinical & Experimental Allergy (2021) Vol. 52, Iss. 1, pp. 167-170
Open Access | Times Cited: 7
Allergen Immunotherapy management during vaccinations: An international survey
Simonetta Masieri, Claus Bachert, Pedro Ojeda, et al.
World Allergy Organization Journal (2021) Vol. 14, Iss. 11, pp. 100601-100601
Open Access | Times Cited: 7
Switching from subcutaneous to sublingual immunotherapy during the maintenance phase in patients with house dust mite allergy
Ploykarn Kiatiwat, Atik Sangasapaviliya, Panitan Pradubpongsa, et al.
Allergy (2023) Vol. 78, Iss. 7, pp. 2019-2021
Closed Access | Times Cited: 2
Aeroallergen immunotherapy associated with reduced risk of severe COVID-19 in 1095 allergic patients
Désirée Larenas‐Linnemann, Blanca María Morfín-Maciel, Martín Bedolla‐Barajas, et al.
World Allergy Organization Journal (2023) Vol. 16, Iss. 5, pp. 100779-100779
Open Access | Times Cited: 2
Allergen-specific immunotherapy practices and course of coronavirus disease 2019 (COVID-19) in patients during COVID-19
Merve Erkoç, Betül Özdel Öztürk, Dilşad Mungan, et al.
Asia Pacific Allergy (2022) Vol. 12, Iss. 1, pp. e6-e6
Open Access | Times Cited: 3
Impact of COVID-19 in allergen immunotherapy: An Italian survey
J Sánchez-López, Enrico Heffler, Giorgio Walter Canonica
Allergologia et Immunopathologia (2022) Vol. 50, Iss. 5, pp. 57-60
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top